Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Right Ventricular Function After Successful Reopening of Right Coronary Versus Left Circumflex Chronic Total Occlusions

15. listopadu 2026 aktualizováno: Amr Abdelbadee Abdelhameed Othman, Assiut University

Changes in Right Ventricular Function Following Successful Right Coronary Versus Left Circumflex Chronic Total Occlusion Revascularization

This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.

The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Design and setting:

Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.

Cohort formation:

Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.

Recruitment schedule:

Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.

Assessments:

Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.

Imaging:

Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.

Anatomical characterization:

Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.

Sample-size rationale:

The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.

Analysis:

The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.

Quality and ethics:

A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.

Typ studie

Pozorovací

Zápis (Odhadovaný)

160

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.

Popis

Inclusion Criteria:

  • Age 18 years or older.
  • Clinically stable, with one native right coronary or left circumflex coronary artery chronic total occlusion, defined by TIMI 0 flow and documented or estimated duration of at least three months.
  • Independently selected for clinically indicated elective PCI.
  • Sinus rhythm and interpretable baseline RV-focused echocardiographic images.
  • Written informed consent before research procedures.
  • For inclusion in the main comparison: technically successful index CTO PCI, defined as residual stenosis less than 30% with final TIMI 3 flow.

Exclusion Criteria:

  • Acute coronary syndrome or myocardial infarction within 30 days.
  • Decompensated heart failure.
  • A second untreated chronic total occlusion.
  • Previous coronary artery bypass graft surgery.
  • Significant congenital heart disease.
  • Moderate or severe valvular heart disease.
  • Severe nonischemic pulmonary disease or pulmonary hypertension dominating RV dysfunction.
  • Persistent atrial fibrillation or paced rhythm preventing comparable analysis.
  • Inadequate baseline RV tracking.
  • Planned non-target revascularization during follow-up; clinically required other-vessel treatment should be completed before baseline when stable.

No arbitrary LVEF threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Successful RCA CTO PCI

Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Successful LCX CTO PCI

Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in right ventricular free-wall longitudinal strain magnitude
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in right ventricular four-chamber longitudinal strain magnitude
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular fractional area change
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular plane systolic excursion
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in tricuspid annular systolic tissue-Doppler velocity
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in right ventricular basal diameter
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in Canadian Cardiovascular Society angina class
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in New York Heart Association functional class
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in basal right ventricular free-wall segmental longitudinal strain magnitude
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in mid right ventricular free-wall segmental longitudinal strain magnitude
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)
Change in apical right ventricular free-wall segmental longitudinal strain magnitude
Časové okno: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Studijní židle: Hatem A. Helmy, MD, Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

31. ledna 2029

Dokončení studie (Odhadovaný)

31. ledna 2029

Termíny zápisu do studia

První předloženo

15. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

15. listopadu 2026

První zveřejněno (Aktuální)

19. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

15. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • AssiutU-CARD-AAAO-0002

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

The IPD might not be shared according to the local institutional policy.

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .